To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
Sign the informed consent and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of the study as specified in the study procedure sheet;
Diagnosed as recurrent or refractory lymphoma, leukemia or myeloma;
Tumor cells express targets for CAR-T cell therapy (results: flow cytometry or Immunohistochemical test confirmation);
Age 14-75 (including threshold), gender unlimited;
Severe cardiac insufficiency;
Have a history of severe lung impairment;
Complicated with other advanced malignant tumors;
Complicated with severe or persistent infection that cannot be effectively controlled;
Hebei Senlang Biotechnology Inc., Ltd.
Lead sponsor
Hebei Taihe Chunyu Biotechnology Co., Ltd
Collaborator